Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Treatment Strategies for VEXAS Syndrome: Multidisciplinary Care, Steroid-Sparing Agents, and Disease-Modifying Therapies
Description
The talk reviews treatment strategies for VEXAS syndrome and emphasizes that care should be multidisciplinary, involving dermatology, hematology, and rheumatology/immunology. Management is organized into three pillars: suppress inflammation, target the underlying clone for disease modification, and provide supportive care. Corticosteroids remain the initial treatment and often work, but patients are frequently steroid-dependent, requiring a very slow taper and careful pursuit of the lowest effective dose because toxicity is common. Conventional DMARDs and TNF inhibitors have generally performed poorly. Among steroid-sparing agents, IL-1 inhibitors have limited benefit overall, with canakinumab appearing better tolerated than anakinra, while IL-6 inhibitors such as tocilizumab and sarilumab provide complete responses in only a minority of patients and can sometimes cause paradoxical worsening. JAK inhibitors, especially ruxolitinib, currently show the most promising response signals, though they carry risks of cytopenias, infection, and thrombosis. For disease modification, the key options are azacitidine and stem cell transplantation; azacitidine can reduce inflammatory activity and lower the UBA1 mutant allele fraction, while transplant may be curative in selected patients but is limited by age, comorbidities, infection risk, and graft-versus-host disease. Supportive care includes thromboprophylaxis, infection prophylaxis, transfusions, growth factors, and biopsy/culture of atypical skin lesions to rule out infection. Response monitoring relies on symptoms, CRP, and blood counts. Prognosis varies by mutation type, with valine mutations doing worst and leucine mutations best; overall five-year survival is about 60%. The talk concludes that expert guidance favors steroids first, reassessment after about 12 weeks, steroid-sparing therapy if more than 10 mg/day is still needed, and consideration of transplant or azacitidine for hematologic disease.
View moreConclusions
- VEXAS management requires a multidisciplinary approach because no single specialty can address the inflammatory, hematologic, and infectious complications alone.
- Glucocorticoids are effective first-line therapy for inflammatory symptoms, but most patients become steroid dependent and require very slow tapering to minimize toxicity.
- Conventional steroid-sparing agents such as IL-1 and TNF inhibitors have limited benefit overall, with IL-6 inhibitors providing only modest response rates.
- JAK inhibitors, especially ruxolitinib, appear to be the most promising anti-inflammatory steroid-sparing option, although they carry important risks of cytopenias, infections, and thrombosis.
- Neither IL-6 nor JAK inhibition appears to meaningfully alter the underlying disease clone or bone marrow failure, so they are not true disease-modifying therapies.
- Targeting the clone with azacitidine can improve both inflammatory disease and molecular burden, including reductions in UBA1 variant allele frequency.
- Allogeneic hematopoietic stem cell transplantation is the only potentially curative treatment, but patient selection, conditioning toxicity, and timing remain major barriers.
- Supportive care is essential to reduce preventable morbidity and mortality, especially through thromboprophylaxis, infection prophylaxis, transfusions, and growth factor support.
- Disease activity and prognosis should be monitored with CRP, blood counts, marrow failure, and mutation subtype, since genotype strongly influences outcomes.
- Overall, current expert guidance favors steroids first, then steroid-sparing agents for persistent disease, and clone-directed therapy such as HSCT or azacitidine for hematologic disease when appropriate.
- Boyadzhieva et al. 2023
- Hadjadj et al. 2024
- Jerome Hadjadj et al. Ann Rheum Dis 2024;83:1358-1367
- Ferrada et al., Blood 2022
- Fernada et al., Blood 2022